<theme image> Big Data - PD1 big data by Shantanu Baruah

Transcription

1 <theme image> Big Data - PD1 big data by Shantanu Baruah WHITEPAPER SEPTEMBER 2014

2 TABLE OF CONTENTS BIG DATA OPPORTUNITIES EVOLVING IN LIFE SCIENCES 3 PD1 THERAPIES ACCELERATOR 3 ENGAGEMENT MODELS 4 TECHNOLOGICAL DEPLOYMENT 5 BARRIERS AND OPPORTUNITIES 5 HCL LIFE SCIENCES & HEALTHCARE 6 LET S CONNECT 6 ABOUT THE AUTHOR 7 ABOUT HCL , HCL TECHNOLOGIES. REPRODUCTION PROHIBITED. THIS DOCUMENT IS PROTECTED UNDER COPYRIGHT BY THE AUTHOR, ALL RIGHTS RESERVED. 2

3 BIG DATA OPPORTUNITIES EVOLVING IN LIFE SCIENCES Pharmaceutical researchers are excited about the results being witnessed around PD1, (Programmed Death 1 receptor) an amino acid cell surface protein molecule. The protein in the host body tends to form a shield around cancerous tumors, inhibiting the body s immune system to fight malignant cells. This has forced doctors to resort to painful chemotherapy and complicated surgical procedures. For years now, pharmaceutical companies have been investing in ways to stimulate the body s natural defense system to disable PD1. Recent trials around PD1 therapies have shown excellent results in the treatment of certain types of cancer. These results have been so good that a number of oncologists have declared that it could lead to a new world in the treatment of the disease. There are many drugs in the making that has been at the forefront of treatment for various forms of cancer. PD1 therapies are also being widely hailed as landmark in the treatment of other forms of cancer such as small cell lung cancer and neck and throat cancer. At the same time, a question is being asked, Can technology help pharmaceutical companies accelerate the use and outcomes of the treatment once it is made available? PD1 anti-body therapies are data problems. That is why technology plays a pivotal role in their future success. PD1 therapies need to be used with significant urgency. In developed countries, metastatic melanoma cases alone have been growing exponentially in number since the 1950s. The condition, a type of skin cancer, is related to exposure to natural or artificial UV radiation (the single biggest source of which is the sun). According to estimates, the annual increase in the incidence rate of melanoma is approximately 3-7% per year worldwide for Caucasians. A 2009 report in the US showed that people were increasingly opting for tanning salons rather than risking being exposed to the sun. As a consequence, tanning salons were making profits of USD5 Bn a year. At the same time, while the medical treatment for metastatic melanoma and other conditions would be available soon, a question arises, How can doctors build on their clinical experience of using the drug to guide patients towards better and more predictable outcomes? In other words, how can technology build on the experience quotient of doctors without them waiting to treat hundreds of patients? We believe that breakthroughs in oncology can be multiplied manifold by deploying technological solutions. PD1 THERAPIES ACCELERATOR Imagine that a patient comes to a Health Care Professional (HCP) with first stage neck cancer. The HCP may have never treated anyone with first stage neck cancer using one of the PD1 anti-body therapies before. This means that the first patient and several more to follow may have to depend on the HCP s advice even though it 2014, HCL TECHNOLOGIES. REPRODUCTION PROHIBITED. THIS DOCUMENT IS PROTECTED UNDER COPYRIGHT BY THE AUTHOR, ALL RIGHTS RESERVED. 3

4 may not be based on first-hand treatment experience (it must be noted here that the HCP s advice could be excellent, but will still leave room for doubt as it is not based on experience). Technology companies such as HCL can change this by helping build the HCP s experience in a matter of minutes using Big Data technologies. Let us assume that one of the pharmaceutical companies -- Company X - developing the treatment captures all PD1-related treatment data on the Cloud-based system. Company X then makes this data available to all HCPs across the world. The HCP logs into the system, looks up similar cases, and begins treating the patient. In effect, the HCP leverages the data ( experience ) accumulated by other doctors using a layer of analytics. The HCP also contributes to the existing data as treatment for the patient progresses, thus adding and updating the information around the manufactured drug. The cloud system keeps track of the critical information regarding treatment and outcomes, such as patient history, condition, diagnosis, prognosis, treatment regime, progress, and contact information of the HCP. If necessary, the HCP can also reach out and connect with others treating similar cases. In all, there are about 6 major pharmaceutical companies working on similar therapies. Clinical trials in cancer research institutes across the world are creating mountains of data around the treatment. This is, therefore, just the right time to build a system to capture and analyze this data. The concept of accelerating clinical outcomes for the PD1-related treatment can be implemented effectively by technology organizations with a deep understanding of the pharmaceutical industry. They should have managed data for clinical trials and other procedures to be able to bring in their domain knowledge and add value to the PD1 Therapies Accelerator. ENGAGEMENT MODELS PD1 Therapies Accelerator can be built around two models: Build a dedicated solution for a pharmaceutical company: Such a one-time deployment will benefit the pharmaceutical company by immediately introducing a differentiator in the treatment (other than clinical efficacy demonstrated during trials and the cost of the treatment). A system to manage, analyze and distribute treatment data could cost nearly USD20 Mn. At the same time, if customized for two to three different organizations, this system could fetch revenues of around USD40-60 Mn. Pharmaceutical companies in the US stand to gain the 14,649 oncologists, along with 68 cancer institutes in the US alone, as customers. The data and analytics system can be used to showcase and improve the outcomes around their PD-1 treatments. The timeframe to develop and validate such a system would be around 24 months. 2014, HCL TECHNOLOGIES. REPRODUCTION PROHIBITED. THIS DOCUMENT IS PROTECTED UNDER COPYRIGHT BY THE AUTHOR, ALL RIGHTS RESERVED. 4

5 Create a revenue sharing model: A platform could be created in partnership with one of the pharmaceutical companies. Each pharmaceutical company developing a PD1- related treatment is a potential pay-per-use customer for such a system. This model has the potential to create over USD200 Mn in business. The system can also unlock an additional revenue steam in the form of payors who can use the information generated on drug performance. TECHNOLOGICAL DEPLOYMENT Conceptual model of the PD1 Therapies Accelerator is shown in Figure 1. HCP CANCER RESEARCH INSTITUTE HOSPITALS CLINICAL TRAILS METASTATIC MELANOMA PATIENT DATA AGGREGATION DATA ANALYTICS REAL-TIME INDUSTRY APPLICABILITY Figure 1: Conceptual Model for PD1 Therapies Accelerator There are three layers to this solution: 1. Data Aggregation: Data must be captured and shipped from point-of-care to a Hadoop-like cluster 2. Data Segmentation: Using Map Reduce 3. BI Application: For queries, analytics, and trend information Using a cloud environment, the system can be made available to hospitals, research institutes, payors, and pharmaceutical companies using a robust connectivity solution. The PD1 Therapies Accelerator will have another critical component -- a customizable dashboard with visualization -- which can be used to improve the way data is presented, consumed, and interpreted by multiple stakeholders. 2014, HCL TECHNOLOGIES. REPRODUCTION PROHIBITED. THIS DOCUMENT IS PROTECTED UNDER COPYRIGHT BY THE AUTHOR, ALL RIGHTS RESERVED. 5

6 BARRIERS AND OPPORTUNITIES The PD1 Therapies Accelerator requires a team of pharmaceutical domain experts, data scientists, Hadoop and Map Reduce Architects, and an Analytics Tool (R, SAS) expert. This team could create a working model and Proof of Concept in the cloud within three months. The challenge will be acquiring real patient data with the attendant compliance concerns. Overcoming this barrier will move the system closer to being HIPPA and HL7 compliant. In summary, the Big Data opportunity presented by PD1 therapies is momentous, and with some effort, it can become a powerful tool in the treatment of cancer. 1. PD-1 and PD-L1 Inhibitors Expected to Change the Landscape of Lung Cancer Treatment, ONCLive: Landscape-of-Lung-Cancer-Treatment 2. A new understanding in the epidemiology of melanoma, The National Center for Biotechnology Information 3. ibid HCL LIFE SCIENCES & HEALTHCARE HCL is a leading provider of Life Sciences and Healthcare Business and Technology services. We are the chosen service provider for enabling new growth drivers for our clients, providing them with industry leading best practices, taking care of their compliance needs and ensuring goldstandard process cycle times. Our clientele includes seven of the top ten global pharmaceutical companies, seven of the top ten medical devices companies, six of the top ten health plans, three of the top five CRO s and two of the top three data providers. Equipped with certified technology experts and domain specialists, HCL offers services in critical areas of the life sciences and healthcare eco system such as drug discovery, clinical development, drug safety, regulatory compliance, manufacturing and plant automation, commercial, Healthcare analytics, Population Health Management [PHM], mhealth, member experience management [MEM], fraud, waste and abuse management [FWA]. LET S CONNECT Please feel free to write to us at contact.lsh@hcl.com 2014, HCL TECHNOLOGIES. REPRODUCTION PROHIBITED. THIS DOCUMENT IS PROTECTED UNDER COPYRIGHT BY THE AUTHOR, ALL RIGHTS RESERVED. 6

7 ABOUT THE AUTHOR Shantanu Baruah Life Sciences & Healthcare Technologist He manages executive relationships, defines and creates technology-led business solutions,creates thought leadership, manages account financials, and leads diversified teams. He also leads technology innovation in the LSH space globally. Prior to his current role, Shantanu was responsible for managing one of HCL s top three accounts globally. Also, in the past, Shantanu headed the digital practice for HCL. y 16+ years of experience in Digital, Enterprise Content Management, and Information Access y Active speaker at forums such as IDC, Gartner events, DUMA (EMC User Conference), and EMC Developers conference. He has authored multiple whitepapers in the digital area y Active contributor to the Apple App creation y Involved with several of HCL s large engagements in transition, delivery, and program governance roles y Holds a Bachelor s degree in Science and Masters in Computer Applications; Currently pursuing MBA from NYU Stern y Based in New Jersey, USA 2014, HCL TECHNOLOGIES. REPRODUCTION PROHIBITED. THIS DOCUMENT IS PROTECTED UNDER COPYRIGHT BY THE AUTHOR, ALL RIGHTS RESERVED. 7

8 ABOUT HCL About HCL Technologies HCL Technologies is a leading global IT services company working with clients in the areas that impact and redefine the core of their businesses. Since its emergence on the global landscape, and after its IPO in 1999, HCL has focused on transformational outsourcing, underlined by innovation and value creation, offering an integrated portfolio of services including software-led IT solutions, remote infrastructure management, engineering and R&D services and business services. HCL leverages its extensive global offshore infrastructure and network of offices in 31 countries to provide holistic, multi-service delivery in key industry verticals including Financial Services, Manufacturing, Consumer Services, Public Services and Healthcare & Life sciences. HCL takes pride in its philosophy of Employees First, Customers Second which empowers its 91,691 transformers to create real value for customers. HCL Technologies, along with its subsidiaries, had consolidated revenues of US$ 5.4 billion, for the Financial Year ended as on 30th June 2014 (on LTM basis). For more information, please visit About HCL Enterprise HCL is a $6.5 billion leading global technology and IT enterprise comprising two companies listed in India HCL Technologies and HCL Infosystems. Founded in 1976, HCL is one of India s original IT garage start-ups. A pioneer of modern computing, HCL is a global transformational enterprise today. Its range of offerings includes product engineering, custom & package applications, BPO, IT infrastructure services, IT hardware, systems integration, and distribution of information and communications technology (ICT) products across a wide range of focused industry verticals. The HCL team consists of over 95,000 professionals of diverse nationalities, who operate from 31 countries including over 505 points of presence in India. HCL has partnerships with several leading global 1000 firms, including leading IT and technology firms. For more information, please visit Hello there! I am an Ideapreneur. I believe that sustainable business outcomes are driven by relationships nurtured through values like trust, transparency and flexibility. I respect the contract, but believe in going beyond through collaboration, applied innovation and new generation partnership models that put your interest above everything else. Right now 95,000 Ideapreneurs are in a Relationship Beyond the Contract with 500 customers in 31 countries. How can I help you?